HEC Pharm is a pharmaceutical manufacturing company that focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases. It is the domestic pharmaceutical manufacturing platform of HEC Group.

We entered into China’s pharmaceutical industry by establishing our predecessor, Yichang Changjiang Pharmaceutical Co., Ltd. in 2001. Up to now, we have been operating for more than 14 years. Due to the rapid growth of our pharmaceutical sales business, we were converted into a joint stock limited company on 11 May 2015, and were listed on the Main Board of the Hong Kong Stock Exchange on 29 December 2015.

Since its establishment, our Company has always followed the motto of “serving the chinese with higher standards”. Meanwhile, we have a strong industrial foundation and a leading competitive edge in the manufacturing and marketing of pharmaceutical products. As of the end of 2015, the Company has manufactured, promoted and sold a total of 33 pharmaceutical products and has a product distribution network throughout country.

We are currently the only manufacturer of oseltamivir phosphate granules in the China market. Our key product Kewei (oseltamivir phosphate) is the leading product in China’s anti-influenza market. During the years from 2013 to 2015, the Company’s oseltamivir phosphate product ranked first in China in terms of sales volume.

HEC Pharm adheres to the implementation of professionalism, branding and differentiation development strategy. It is committed to the establishment of a professional marketing team, a steady and innovative market operation and a strategic integration of resources, in order to create a unique brand characteristics and core competitiveness in the industry and create value for our customers and partners to the greatest.

In the future, the Company will further develop its product lines and markets, enhance international production standards and quality of the products and continue to expand the coverage of marketing and sales in order to facilitate the additional growth of our operation and profitability, and strive for more economic benefits and interests for the investors.